Has Jilbert Eradat, MD received payments from drug or device companies?

Yes. Drug and device makers reported $109,801 in general payments to Jilbert Eradat, MD across 139 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Jilbert Eradat, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Jilbert Eradat, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Jilbert Eradat, MD

Vascular & Interventional Radiology · Los Angeles, CANPI 1083927115

Payments from drug & device makers

What this record shows

This record is dominated by other: $96,831 of the $109,801 with a category attached, or 88.2%. Angiodynamics, Inc. accounts for 89.4% of it on its own, with 20 other manufacturers making up the rest. 2025 is the largest year on record at $35,783, more than ten times the $2,100 reported in 2019. Among vascular & interventional radiology clinicians in CA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$109,801in general payments, 2019–2025

Across 139 payments — averaging $789.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Angiodynamics, Inc.$98K
Abbott$5K
Cardiovascular Systems Inc.$2K
Terumo Medical Corporation$1K
Merit Medical Systems Inc$1K
Baxter Healthcare$858
plus $2K from 15 others

What the payments were for

Consulting fees$1180%
Travel & lodging$7,0946%
Food & beverage$5,7575%
Other$96,83188%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Angiodynamics, Inc.	17	$98,206
Abbott	47	$5,064
Cardiovascular Systems Inc.	10	$1,780
Terumo Medical Corporation	8	$1,348
Merit Medical Systems Inc	10	$1,039
Baxter Healthcare	2	$858
Lemaitre Vascular, Inc.	12	$304
Medtronic	5	$247
Asahi Intecc USA, Inc.	2	$179
Philips North America LLC	2	$145
Organogenesis Inc.	1	$125
Biotronik Inc.	4	$113
Bard Peripheral Vascular, Inc.	6	$108
Boston Scientific	3	$83
BD	3	$54
Nevro Corp.	2	$50
Sirtex Medical Inc	1	$28
Cordis US CORP.	1	$22
Teleflex LLC	1	$18
Mozarc Medical US LLC	1	$17
Veryan Medical Incorporated	1	$13

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

Auryon Laser System 100-120 Vac$96,141
AngioVac$1,781
Peripheral Orbital Atherectomy System$1,462
OMNILINK ELITE$1,228
GLIDESHEATH SLENDER$1,226
Perclose ProStyle$1,112
PERCLOSE PROGLIDE$1,024
Embosphere Microspheres$911
SwiftNINJA Sterble Cor Micro$911
OPTIS$319
HawkOne$158
Puraply Antimicrobial$125
Turbo Elite$125
Omnilink Elite vascular stent system$118

How this compares

$109,801 in reported general payments places this provider in the 90th percentile of 504 vascular & interventional radiology providers in California.

See all vascular & interventional radiology providers in California →

Medicare billing

Part B allowed, 2024

$1,138,904

Medicare patients

248

Services billed

2,390

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
EliquisApixaban	35	$24,148
XareltoRivaroxaban	20	$18,970
ClopidogrelClopidogrel Bisulfate	57	$576
Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav	43	$377
Doxycycline Hyclate	14	$147

Paid to pharmacies, not to this prescriber.

Other vascular & interventional radiology in Los Angeles

Keith TerasakiLos Angeles$1.7M
Edward LeeLos Angeles$1.4M
Siddharth PadiaLos Angeles$960K
Satoshi TateshimaLos Angeles$764K
Navid EghbaliehLos Angeles$639K
John MoriartyLos Angeles$527K
Justin McWilliamsLos Angeles$265K
Jessica StewartLos Angeles$254K
Evan LehrmanLos Angeles$218K
Steven RamanLos Angeles$211K

See the full list for California →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →